A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Sumanta K. Pal, Catherine Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y.C. Heng, Brian Shuch, Mark Stein, Maria Tretiakova, Peter Humphrey, Adebowale Adeniran, Vivek Narayan, Georg A. Bjarnason, Ulka Vaishampayan, Ajjai Alva, Tian Zhang, Scott Cole, Melissa Plets, John Wright, Primo N. Lara

Research output: Contribution to journalArticlepeer-review

27 Scopus citations
Original languageEnglish (US)
Pages (from-to)695-703
Number of pages9
JournalThe Lancet
Volume397
Issue number10275
DOIs
StatePublished - Feb 20 2021
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial'. Together they form a unique fingerprint.

Cite this